• Consensus Rating: Hold
  • Consensus Price Target: $50.00
  • Forecasted Upside: 25.25%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$39.92
▼ -0.01 (-0.03%)

This chart shows the closing price for SRDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Surmodics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRDX

Analyst Price Target is $50.00
▲ +25.25% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Surmodics in the last 3 months. The average price target is $50.00, with a high forecast of $71.00 and a low forecast of $43.00. The average price target represents a 25.25% upside from the last price of $39.92.

This chart shows the closing price for SRDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Surmodics. This rating has held steady since May 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Needham & Company LLCReiterated RatingHold
8/5/2024Needham & Company LLCReiterated RatingHold
5/30/2024Barrington ResearchReiterated RatingOutperform ➝ Market Perform
5/29/2024Lake Street CapitalReiterated RatingBuy ➝ Hold$43.00
5/29/2024SidotiReiterated RatingBuy ➝ Neutral$43.00
5/29/2024Needham & Company LLCReiterated RatingBuy ➝ Hold
5/2/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$71.00 ➝ $71.00
5/1/2024Needham & Company LLCLower TargetBuy ➝ Buy$47.00 ➝ $43.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$47.00
2/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$44.00 ➝ $47.00
11/9/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$69.00 ➝ $71.00
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$50.00 ➝ $44.00
8/2/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$36.00 ➝ $50.00
6/21/2023Barrington ResearchBoost Target$60.00 ➝ $69.00
6/13/2023Needham & Company LLCUpgradeHold ➝ Buy$36.00
2/13/2023Needham & Company LLCDowngradeBuy ➝ Hold
2/7/2023Barrington ResearchLower TargetOutperform$61.00 ➝ $60.00
2/7/2023Needham & Company LLCLower TargetBuy$46.00 ➝ $34.00
1/20/2023Barrington ResearchLower TargetOutperform$70.00 ➝ $61.00
2/4/2022Needham & Company LLCLower TargetBuy$70.00 ➝ $58.00
11/10/2021Needham & Company LLCLower TargetBuy$76.00 ➝ $70.00
9/8/2021Needham & Company LLCBoost TargetBuy$68.00 ➝ $76.00
2/10/2021Barrington ResearchBoost TargetOutperform$63.00 ➝ $70.00
2/5/2021Needham & Company LLCReiterated RatingBuy$61.00
8/6/2020Barrington ResearchReiterated RatingBuy$63.00
7/23/2020Needham & Company LLCUpgradeHold ➝ Buy$61.00
6/10/2020Barrington ResearchReiterated RatingBuy$62.00
6/1/2020Lake Street CapitalBoost TargetBuy$50.00 ➝ $76.00
4/30/2020Barrington ResearchReiterated RatingBuy$56.00
4/30/2020Needham & Company LLCReiterated RatingHold
2/6/2020Barrington ResearchReiterated RatingOutperform$62.00 ➝ $56.00
2/6/2020Lake Street CapitalUpgradeHold ➝ Buy$50.00
2/6/2020Needham & Company LLCDowngradeHold
12/11/2019Needham & Company LLCDowngradeBuy ➝ Hold
(Data available from 12/6/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/10/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/9/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/9/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/8/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/7/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/7/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/6/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/6/2024

Current Sentiment

  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Surmodics logo
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Read More

Today's Range

Now: $39.92
Low: $39.90
High: $40.00

50 Day Range

MA: $38.58
Low: $37.50
High: $39.93

52 Week Range

Now: $39.92
Low: $25.17
High: $42.44

Volume

4,716 shs

Average Volume

226,286 shs

Market Capitalization

$571.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Surmodics?

The following Wall Street sell-side analysts have issued stock ratings on Surmodics in the last twelve months: Barrington Research, Lake Street Capital, Needham & Company LLC, Sidoti, and StockNews.com.
View the latest analyst ratings for SRDX.

What is the current price target for Surmodics?

0 Wall Street analysts have set twelve-month price targets for Surmodics in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 25.3%. Barrington Research has the highest price target set, predicting SRDX will reach $71.00 in the next twelve months. Sidoti has the lowest price target set, forecasting a price of $43.00 for Surmodics in the next year.
View the latest price targets for SRDX.

What is the current consensus analyst rating for Surmodics?

Surmodics currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SRDX, but not buy more shares or sell existing shares.
View the latest ratings for SRDX.

What other companies compete with Surmodics?

How do I contact Surmodics' investor relations team?

Surmodics' physical mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company's listed phone number is (952) 500-7000 and its investor relations email address is [email protected]. The official website for Surmodics is www.surmodics.com. Learn More about contacing Surmodics investor relations.